- Location
Pharmacyclics
"-
JNJ and PCYC Have Won Approval From FDA for Their Breakthrough Therapy Imbruvica
Nov 15, 2013Johnson & Johnson (JNJ) subsidiary Janssen Biotech and Pharmacyclics (PCYC) have won approval from the US Food and Drug Administration (FDA) for their breakthrough therapy Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma ...
Tags: Johnson&Johnson, MCL Patients
-
Janssen-Cilag Has Submitted MAA to EMA
Nov 1, 2013Janssen-Cilag (Janssen), a subsidiary of Johnson & Johnson pharmaceutical firm, has submitted marketing authorization application (MAA) to the European Medicines Agency (EMA) for the approval of once daily oral drug ibrutinib for the ...
Tags: Blood Cancer Medicine, Medicine
-
NDA for The Investigational Oral BTK Inhibitor,Ibrutinib,Has Been Accepted by The US FDA
Sep 2, 2013Clinical-stage biopharmaceutical company Pharmacyclics' new drug application (NDA) for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been accepted by the US FDA for two B-cell malignancy indications. ...
Tags: Solvay Group, Medicine
-
Janssen Research & Development Is Seeking FDA Approval for Use Ibrutinib in The Treatment
Jul 12, 2013Janssen Research & Development is seeking FDA approval for use of ibrutinib in the treatment of previously treated patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). The ...
Tags: FDA Approval, Janssen
-
Abbott Has Entered Into a Collaboration Agreement
Feb 25, 2013Abbott has entered into a collaboration agreement with Janssen Biotech and Pharmacyclics to develop a molecular companion diagnostic test for investigational leukemia therapy. Under the agreement, Abbott will leverage its proprietary ...
Tags: leukemia therapy, Abbott, Pharmacyclics